A trial of Moderna’s norovirus vaccine in the U.S. has been put on hold by the FDA over a reported case of neurological ...

Otsuka has dumped a clutch of clinical cancer candidates on Valentine's day. | Otsuka has broken up with a clutch of clinical ...

Fresh off winning a Nobel Prize last year, and previously tackling antibodies and peptides, the University of Washington’s ...

Corbus Pharmaceuticals has posted the first Western clinical data on its would-be rival to Pfizer’s Padcev. The overall ...

After its depression candidate failed a phase 3 trial and disappointed analysts, Neumora is shaking up its leadership team.

Newleos Therapeutics is making its debut with $93.5 million aimed at developing safer and more effective neuroscience ...

Boston biotech Kojin Therapeutics is closing its doors, citing four funding challenges and a few valuable lessons learned.  ...

Volta Medical put forward new data showing its artificial-intelligence-guided ablation procedures were able to improve ...

“As administrations change, federal agencies’ leadership often changes to align with the incoming president’s priorities,” ...

Two months after Allogene abandoned plans for its CAR-T in leukemia, analysts have suggested that fresh phase 1 data in ...

Sanofi-backed Abcuro has secured $200 million in series C funds to power its anti-KLRG1 antibody through a phase 2/3 muscle ...

Having kicked off the year with a T-cell engager deal, AbbVie has returned to the modality. | Having kicked off the year with ...